Rising Psoriatic Arthritis Diagnoses Fueling The Growth Of The Market Due To Increasing Early Detection And Cost-Effective Treatment Demand Is Supporting Development Across The Psoriasis Biosimilars Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Psoriasis Biosimilars Market During 2026–2030?

The psoriasis biosimilars market size has experienced significant expansion recently. Its expansion is projected to increase from $8.16 billion in 2025 to $9.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.3%. Historically, this growth has been driven by factors such as the substantial expense of reference biologics, restricted patient access to appropriate treatment, the rising incidence of moderate to severe psoriasis, enhanced physician recognition and prescribing habits, and the initial authorizations of TNF-alpha inhibitors.

The psoriasis biosimilars market size is projected for significant expansion over the coming years. It is anticipated to reach $13.79 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.0%. This forecasted growth is primarily driven by the introduction of new biosimilars for infliximab, etanercept, and adalimumab, alongside the widening reach of hospital and online pharmacy networks, increased spending on dermatological healthcare, the growing uptake of patient assistance programs, and an increase in clinical trials for innovative biosimilars. Key developments expected during this period involve the increasing use of affordable psoriasis biosimilars, a greater emphasis on patient accessibility and cost-effectiveness, the rise of subcutaneous and intravenous delivery methods, the expansion of distribution channels through hospitals and retail pharmacies, and the creation of targeted treatments for various forms of psoriasis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

What Influential Factors Are Boosting The Psoriasis Biosimilars Market Demand?

The increasing diagnosis rates of psoriatic arthritis are anticipated to fuel the expansion of the psoriasis biosimilars market moving forward. Psoriatic arthritis is defined as a persistent autoimmune disorder leading to inflammation in both joints and skin, frequently observed in individuals who have previously had psoriasis. The diagnosis rates for psoriatic arthritis are on the rise, primarily attributed to enhanced screening procedures for individuals with psoriasis. These protocols allow for earlier and more precise diagnosis by detecting minor joint symptoms that might have been overlooked before. Psoriasis biosimilars aid in the management of psoriatic arthritis by offering cost-effective alternatives to existing biologic treatments, thereby effectively alleviating joint inflammation and skin manifestations. For example, data from August 2025, provided by the National Psoriasis Foundation (NPF), a US-based non-profit patient advocacy organization, indicates that psoriatic arthritis impacts approximately 1 in 3 individuals with psoriasis. Furthermore, up to 2.4 million Americans are affected by psoriatic arthritis, and over 15% of those with psoriasis might also suffer from undiagnosed psoriatic arthritis, underscoring both growing awareness and ongoing underdiagnosis of the condition. Consequently, the escalating rates of psoriatic arthritis diagnoses are propelling the expansion of the psoriasis biosimilars market.

Which Segment Divisions Form The Structure Of The Psoriasis Biosimilars Market?

The psoriasis biosimilars market covered in this report is segmented –

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

What Trends Are Influencing The Future Of The Psoriasis Biosimilars Market?

Key companies in the psoriasis biosimilars market are dedicating efforts to introducing innovative options, such as biosimilars tailored for plaque psoriasis, aiming to boost treatment availability, decrease healthcare expenditures, and enhance patient outcomes. Biosimilars for plaque psoriasis represent more economical, highly similar alternatives to established biologic drugs utilized for managing this chronic autoimmune skin condition, characterized by red, scaly patches. As an illustration, in May 2025, Sandoz Group AG, a Switzerland-based entity focused on generic pharmaceuticals and biosimilars, unveiled the Pyzchiva autoinjector, marking the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva has received approval for treating adults with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, in addition to pediatric patients aged six years and older (weighing over 60 kg) affected by plaque psoriasis. Crafted to improve patient adherence and lifestyle quality, the autoinjector offers precise automatic dosing, reduced pain during injection, a compact build, and adaptable storage solutions for more comfortable self-administration.

Who Are The Firms Contributing To The Psoriasis Biosimilars Market Ecosystem?

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

Access The Complete Psoriasis Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

Which Region Is The Dominant Market In The Psoriasis Biosimilars Market?

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Psoriasis Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

Browse Through More Reports Similar to the Global Psoriasis Biosimilars Market 2026, By The Business Research Company

Connected Rail Market Report 2026

https://www.thebusinessresearchcompany.com/report/connected-rail-global-market-report

Rail Road Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/rail-road-construction-global-market-report

Freight Railcar Parts Market Report 2026

https://www.thebusinessresearchcompany.com/report/freight-railcar-parts-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795